Baird Capital invests in Strata Oncology

Baird Capital invests in Strata Oncology

June 2, 2016

Baird Capital's Venture Capital team is pleased to announce that it has completed an investment in Strata Oncology (Strata), a precision medicine company that provides no-cost tumor sequencing to advanced cancer patients and identifies matching clinical trials for them with pharmaceutical partners.

The equity investment was co-led by Baird Capital's Venture Capital Fund IV along with Arboretum Ventures and existing investor Michigan eLab. The financing will fuel Strata's state-of-the-art tumor sequencing operation and implementation of the Strata Trial, a nation-wide effort aimed at substantially increasing the number of enrollments in precision medicine clinical trials.

Ann Arbor-based Strata has also entered into a strategic partnership with Thermo Fisher Scientific, which will serve as the technology provider and contribute Ion S5TM XL next-generation sequencing systems, AmpliSeqTM technology, and OncomineTM assays.

As part of this investment, Nicole Walker will join Strata Oncology's board of directors.

Contact Investment Team

Nicole Walker
[email protected]

David Gregorka
Venture Partner
[email protected]

Momei Qu
Senior Associate
[email protected]